{"id":"injection-of-cyclosporin","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-30","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Neurotoxicity (headache, paresthesia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporin binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The injectable formulation allows systemic immunosuppression for transplant rejection prevention and severe autoimmune conditions.","oneSentence":"Cyclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:17.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis)"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT06642909","phase":"PHASE2","title":"A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2024-11-13","conditions":"Primary Membranous Nephropathy","enrollment":135},{"nctId":"NCT05398653","phase":"PHASE1, PHASE2","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2022-02-24","conditions":"Primary Membranous Nephropathy","enrollment":94},{"nctId":"NCT07029204","phase":"EARLY_PHASE1","title":"Intralesional Cyclosporine for Alopecia Areata","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-08-19","conditions":"Alopecia Areata","enrollment":12},{"nctId":"NCT01502774","phase":"PHASE3","title":"Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-04","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":970},{"nctId":"NCT05862233","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-06-02","conditions":"Primary Membranous Nephropathy","enrollment":150},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT07043985","phase":"NA","title":"Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study","status":"COMPLETED","sponsor":"Badr University","startDate":"2018-01-03","conditions":"Tissue Modification After Vit c Injection","enrollment":20},{"nctId":"NCT05153070","phase":"PHASE2","title":"Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-21","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT07029139","phase":"PHASE2","title":"A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-06-30","conditions":"Primary Membranous Nephropathy","enrollment":156},{"nctId":"NCT05149313","phase":"PHASE3","title":"A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2021-12-23","conditions":"Dermatitis, Atopic, Eczema","enrollment":331},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT06470191","phase":"PHASE2, PHASE3","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2024-07-30","conditions":"Primary Membranous Nephropathy","enrollment":216},{"nctId":"NCT05789615","phase":"","title":"Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"CMV Infection, Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT03079089","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2017-06-30","conditions":"Refractory or Relapsed Lymphoid Haemopathy","enrollment":40},{"nctId":"NCT06424639","phase":"PHASE4","title":"Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05","conditions":"Aplastic Anemia","enrollment":58},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT05056779","phase":"PHASE3","title":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable","status":"WITHDRAWN","sponsor":"Galderma R&D","startDate":"2023-01","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":""},{"nctId":"NCT06009497","phase":"PHASE4","title":"Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Non Severe Aplastic Anemia","enrollment":44},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT03035422","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2018-01-15","conditions":"Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02015351","phase":"NA","title":"Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization","enrollment":9},{"nctId":"NCT02328755","phase":"PHASE1, PHASE2","title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2015-01","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT04878770","phase":"NA","title":"NMF-CsA-Dupi Trial","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2021-08-16","conditions":"Dermatitis, Atopic","enrollment":318},{"nctId":"NCT04895423","phase":"PHASE4","title":"Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood","status":"UNKNOWN","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2021-11-25","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT03209219","phase":"PHASE3","title":"Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2017-06-30","conditions":"Behçet Disease, Uveitis","enrollment":28},{"nctId":"NCT03287635","phase":"PHASE4","title":"Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2018-07-01","conditions":"Dry Eye Disease","enrollment":19},{"nctId":"NCT02462252","phase":"PHASE2","title":"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2015-10","conditions":"Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT01193660","phase":"NA","title":"Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy","status":"COMPLETED","sponsor":"Sung Kwang Medical Foundation","startDate":"2010-05","conditions":"Cerebral Palsy","enrollment":105},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT02404025","phase":"PHASE2","title":"Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"Aplastic Anemia","enrollment":10},{"nctId":"NCT00987207","phase":"PHASE3","title":"Pharmacological Postconditioning During the Aortic Valvular Surgery","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Aortic Valvular Surgery","enrollment":56},{"nctId":"NCT01527240","phase":"PHASE2","title":"Neuroprotection Impact of Cyclosporin A in Cerebral Infarction","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-10","conditions":"Stroke","enrollment":126},{"nctId":"NCT02934217","phase":"PHASE3","title":"Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-03","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":868},{"nctId":"NCT00249808","phase":"PHASE4","title":"A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-12-13","conditions":"Psoriasis","enrollment":1266},{"nctId":"NCT01399281","phase":"","title":"Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2011-12","conditions":"Juvenile Idiopathic Arthritis","enrollment":9000},{"nctId":"NCT00006184","phase":"PHASE2","title":"Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-02-08","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT02547714","phase":"PHASE4","title":"Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-16","conditions":"Plaque Psoriasis","enrollment":34},{"nctId":"NCT02904772","phase":"PHASE2","title":"Alipogene Tiparvovec for the Treatment of LPLD Patients","status":"WITHDRAWN","sponsor":"UniQure Biopharma B.V.","startDate":"2016-10","conditions":"LPL Deficiency","enrollment":""},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT03192657","phase":"PHASE2","title":"Basiliximab Treating Interstitial Pneumonia of CADM","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-07","conditions":"Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis","enrollment":100},{"nctId":"NCT03180723","phase":"PHASE3","title":"Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-07-01","conditions":"Membranoproliferative Glomerulonephritis","enrollment":30},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT02397213","phase":"PHASE2","title":"Ciclosporin to Protect Renal Function In Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-04","conditions":"Acute Kidney Injury","enrollment":155},{"nctId":"NCT02042027","phase":"PHASE1","title":"Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2014-07","conditions":"Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation","enrollment":""},{"nctId":"NCT02028416","phase":"NA","title":"Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia","status":"UNKNOWN","sponsor":"National Institute of Blood Disease Center, Pakistan","startDate":"2013-09","conditions":"Aplastic Anemia","enrollment":60},{"nctId":"NCT01901471","phase":"PHASE2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT02660684","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2008-02","conditions":"Graft Versus Host Disease","enrollment":39},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01650662","phase":"PHASE3","title":"CYCLosporinE A in Reperfused Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2012-01","conditions":"Acute Myocardial Infarction","enrollment":410},{"nctId":"NCT01817322","phase":"PHASE4","title":"Kidney Graft Function Under the Immunosuppression Strategies","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Chronic Renal Disease","enrollment":140},{"nctId":"NCT01002859","phase":"PHASE2","title":"Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2009-04","conditions":"Coronary Artery Bypass Surgery, Cardiopulmonary Bypass","enrollment":50},{"nctId":"NCT01692834","phase":"PHASE1","title":"A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2009-06","conditions":"Healthy","enrollment":65},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01526850","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-02","conditions":"Chronic Graft Versus Host Disease","enrollment":100},{"nctId":"NCT01446484","phase":"PHASE1, PHASE2","title":"Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection","status":"UNKNOWN","sponsor":"Pirogov Russian National Research Medical University","startDate":"2011-10","conditions":"End-Stage Renal Disease, Kidney Failure","enrollment":30},{"nctId":"NCT01109498","phase":"PHASE2, PHASE3","title":"Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]","status":"UNKNOWN","sponsor":"Amsterdam Molecular Therapeutics","startDate":"2007-08","conditions":"Familial Lipoprotein Lipase Deficiency","enrollment":14},{"nctId":"NCT00891306","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects","status":"COMPLETED","sponsor":"Amsterdam Molecular Therapeutics","startDate":"2009-02","conditions":"Familial Lipoprotein Lipase Deficiency","enrollment":5},{"nctId":"NCT00149890","phase":"PHASE3","title":"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Liver Transplantation, Infection","enrollment":77},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT00149994","phase":"PHASE4","title":"Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-12","conditions":"Liver Transplant","enrollment":171},{"nctId":"NCT00856752","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine","status":"COMPLETED","sponsor":"Norgine","startDate":"2006-06","conditions":"Pharmacokinetics","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclosporin A (CicloMulsion, verum)"],"phase":"phase_3","status":"active","brandName":"Injection of Cyclosporin","genericName":"Injection of Cyclosporin","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients, Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}